CD24+/CD38- as new prognostic marker for non-small cell lung cancer
Feridoun Karimi-Busheri1, Aghdass Rasouli-Nia, Victoria Zadorozhny
1Stem Cell Department, NovaRx Corporation, 6828 Nancy Ridge Drive, San Diego, USA. fkarimi@ualberta.ca.
Background:
Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer.
Methods:
In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel.
Results:
We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM.
Conclusions:
We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
